Meet with... Leaders from the National Cancer Institute's SBIR program

Thursday, May 1 2014
8:30 am – 3:00 pm

This event was posted by Johnson & Johnson

Location: LabCentral | 700 Main St | Cambridge, MA 02139

Did you know that companies like Medimmune and Affymetrix each received SBIR funding during their early stages to help grow their companies and develop compelling new products? There have been exciting new developments with SBIR in the past couple of years that you might not be aware of. Venture-backed small businesses are now eligible to apply and companies can now compete directly for larger Phase II SBIR awards. The National Cancer Institute SBIR & STTR is currently funding 372 projects in the areas of IT, diagnostics, imaging, devices, therapeutics, and tools for basic research? Join us for a chance to hear about the SBIR & STTR funding process and apply for a one-on-one meeting with a representative from the NCI.

 

PROGRAM OVERVIEW

The Federal Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs are a critical source of non-dilutive financing for early stage companies, providing over $115M in fiscal year 2014 to develop next generation technologies. These funding programs help fill the gap in the availability of early stage funding created when investors and strategic partners moved towards clinical-stage investments. SBIR funds serve as a key bridge between initial angel funding and more significant angel capital, venture capital, or strategic partnerships.

 

Hear from Michael Weingarten, Director for the NCI SBIR Development Center, about the various new NCI SBIR program initiatives and funding opportunities. The presentation will include a discussion of the expanded eligibility for SBIR funding, the new Direct-to-Phase II solicitation, and the NCI SBIR Bridge award which provides an additional $3M in SBIR funding beyond Phase II to match investments by non-federal investors.

 

Andrew Kurtz, Program Director & Team Leader with the NCI SBIR Development Center, will provide guidance on preparing a competitive application which will include an overview of the elements that NCI looks for when reviewing applications, a discussion on the proper stage of development for each Phase, and answers to FAQs.

 

Following the presentation and Q&A, don't miss this opportunity to introduce yourself to the NCI SBIR Development Center representatives during the networking lunch. For companies who apply online and are approved, one-on-one meetings with the NCI SBIR program representatives will provide an opportunity to further discuss your company.

 

Don't miss the opportunity to meet one-on-one with directors from the NCI SBIR Development Center: apply today!

 

AGENDA

8:30am | Registration and Networking

9:00am | Welcome

9:15am | Presentation and Q&A

11:15am | Networking Lunch

12:00-3:00pm | One-on-one Meetings*

*Companies must apply ahead of time and be approved for a one-on-one meeting. The application period ends April 17.

 

NATIONAL CANCER INSTITUTE PARTICIPATING REPRESENTATIVES

Michael Weingarten, MS | Director, SBIR Development Center, National Cancer Institute

Andrew Kurtz, PhD | Program Director & Team Leaders, SBIR Development Center, National Cancer Institute

Todd Haim, PhD | Program Director, SBIR Development Center, National Cancer Institute

 

ABOUT THE NATIONAL CANCER INSTITUTE

The National Cancer Institute (NCI) is part of the National Institutes of Health (NIH), which is one of 11 agencies that compose the Department of Health and Human Services (HHS). The NCI, established under the National Cancer Institute Act of 1937, is the Federal Government's principal agency for cancer research and training. The National Cancer Act of 1971 broadened the scope and responsibilities of the NCI and created the National Cancer Program. Over the years, legislative amendments have maintained the NCI authorities and responsibilities and added new information dissemination mandates as well as a requirement to assess the incorporation of state-of-the-art cancer treatments into clinical practice. The National Cancer Institute coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients.

 

FEES

$25 | Presentation & Lunch Only [$35 Onsite]

$25 | One-on-One Meeting Only - Accepted Companies only [Free Application closing on April 17]

Info and registration: http://jlabslc-nci2014-massbio.eventbrite.com

 

LOCATION

LabCentral

700 Main St

Cambridge, MA 02139

 

ABOUT THE MEET WITH... SERIES

The purpose of the Meet with Series events sponsored by Janssen Labs is to help start-up entrepreneurs as well as the academic community connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include: Wellcome Trust, MedImmune Ventures, NCI, Mercury Fund, Correlation Ventures, Breakout Labs, and Thomas McNerney & Partners

 

EVENT CONTACT

Madelaine Holden

mholden3@its.jnj.com

858.242.1503

Share MassBio

 

Janitronics

EvaluatePharma
 

MassBio